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Most if not all neoplasias show a directly or indirectly deregulated cell cycle. Targeting its regulatory molecules, the cyclin-
dependent kinases, as a therapeutic mode to develop new anticancer drugs, is being currently explored in both academia and
pharmaceutical companies. The development of new compounds is being focused on the many features of the cell cycle with
promising preclinical data in most ﬁelds. Moreover, a few compounds have entered clinical trials with excellent results
maintaining the high hopes. Thus, although too early to provide a cell cycle target based new commercial drug, there is no
doubt that it will be an excellent source of new anticancer compounds.
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Mammalian cell division is timely regulated by a family of protein
kinase holoenzymes, the cyclin-dependent kinases (CDKs) and
their heterodimeric cyclin partners. Regulation of CDK activity
occurs at multiple levels, including cyclin synthesis and degrada-
tion, phospho- and dephosphorylation, CDK inhibitor (CKI)
protein synthesis, binding and degradation, and subcellular locali-
sation (Pines, 1995; Harper, 1997; Cerutti and Simanis, 2000).
Orderly progression through the cell cycle involves coordinated
activation of the CDK protein by binding to the cyclin partner
(Table 1). Different CDK-cyclin complexes operate during different
phases of the cell cycle. The activation also requires the presence of
CDK-activating kinase (CAK) that phosphorylates CDK subunits at
residues Thr 160/161, and dephosphorylates residues Thr 14 and
Tyr 15 by CDC25 phosphatase (Clarke, 1995; Draetta and Eckstein,
1997). Active CDK-cyclin complexes phosphorylate target
substrates, including members of the ‘pocket protein’ family (the
product of the retinoblastoma susceptibility gene, pRb, and the
related p107 and p130 proteins) (Grana et al, 1998).
Endogenous inhibition of CDKs also occurs by two families of
regulatory proteins induced under antimitogenic stimuli: the





INK4d, which contains conserved ankyrin motifs and speciﬁcally
inhibits CDK4 and CDK6 (Carnero and Hannon, 1998). The CIP/
KIP family includes p21
cip1/waf1, p27
kip1 and p57
kip2, which share a
broader range of inhibition and act in a concentration-dependent
manner (Hengst and Reed, 1998). All CKIs cause G1 arrest when
overexpressed in cells by association and inhibition of the CDKs.
INK4 proteins dissociate the cyclinD/CDK complexes and redistri-
butes the CIP/KIP proteins to CDK2 producing a double
inhibition. At low concentration, CIP/KIP family proteins enhance
CDK4 association to cyclin D increasing the activity of the
complex. At high concentrations they inhibit the kinase activity,
presumably by increasing the stechiometry in the CDK complexes
(Sherr and Roberts, 1999).
Proper regulation of CDK activity is essential for the ordered
execution of the processes controlling cell-growth, complete DNA
replication and mitotic distribution of chromosomes to daughter
cells. To ensure this, surveillance mechanisms function as check-
points to control cell-cycle progression (Nurse, 1997). These
checkpoints ensure that growth promoting or inhibiting signals
transmit their effects on cell cycle progression by modulating
CDK activity. After the proliferative stimuli (growth factors and
oncogenes) inducing cell proliferation, a ﬁrst checkpoint (the
Restriction point) at late G1 integrates both positive and negative
external and internal signals before the cell commits itself to
another round of DNA replication. More speciﬁcally, this sensitive
period includes the mid-to-late G1 phase culminating at the
Restriction point (or R point), and the onset of DNA replication.
In mammalian cells the R point is regulated mainly by the CDKs
bound to the D type of cyclins (Draetta, 1994; Sherr, 1994). The
G1 checkpoint ensures proper phosphorylation of the pRb protein.
Phosphorylated pRb releases E2F transcription factors that are
bound to DP1 forming the transcriptionally active heterodimer
E2F-DP1 (Weinberg, 1995; Muller and Helin, 2000). This results
in the expression of proteins (including cyclins A and E) necessary
to initiate and complete DNA synthesis. Consistent with its role in
the cell cycle, several E2F family member genes have been shown to
function as oncogenes in culture. Removal of sequences involved in
regulation by pRb, or inclusion of DP1, increases the oncogenic
potential of E2F1. Also, a role for the E2F1 gene as a tumour
suppressor has recently been established through the generation
of mice lacking a functional E2F1 allele. Another important check-
point occurs at the G2/M transition which ensures proper
chromosome segregation to the daughter cells (Ohi and Gould,
1999). This checkpoint is controlled by CDK1 (CDC2) bound to
cyclins B and A. Although it appears that the oncogenic defects
may target any major transition or checkpoint of the cell cycle,
the step strikingly deregulated most frequently is G1 to S transi-
tion.
The vast majority of human neoplasias have abnormalities in
one or more of its cell cycle components, due to overexpression
of positive regulators of CDK function and/or a decrease in the
negative regulators of CDK function resulting in hyper activation
of CDKs (Table 2). However, the involvement of the cell cycle
mechanism in tumorigenesis is not restricted to the direct deregu-
lation of one or more of its components. Tumorigenic properties Received 30 November 2001; accepted 10 May 2002
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cycle machinery (Hanahan and Weinberg, 2000).
Myc is a positive regulator of G1-speciﬁc CDKs in particular
cycE/CDK2 complexes. Myc acts through at least three different
pathways which can enhance CDK function; (1) Functional inacti-
vation of the CDK inhibitor p27
kip1 and probably also p21
cip1/waf1
and p57
kip2; (2) induction of the CDK-activating phosphatase
CDC25A and (3) deregulation of cyclin E expression (Amati et
al, 1998).
Ras transduces mitogenic stimuli in response to tyrosine-kinase
receptors, and its function is required in G1 for passage through
the R-point (Malumbres and Pellicer, 1998; Crespo and Leon,
2000). Ras activity is required for the phosphorylation of pRb in
response to mitogenic signalling, and functional inactivation of
Ras induces G1 arrest in pRb-positive but not in pRb-negative
cells. The mitogenic signal mediated by Ras and Raf may act
through the induction of cyclin D1 and/or the degradation of
p27
kip1. Activated Ras protein, or its effector Raf, maintain a
constitutive mitogenic signal mimicking a constitutive activation
of Tyr kinase receptors. Other oncogenes such as Erb2, src,v - sis,
may act, at least partially, by similar mechanisms.
Abnormalities in the p53 tumour suppressor gene are the most
frequent molecular events in human and animal neoplasia. p53 is a
critical nodal point of converging pathways from diverse cellular
insults which can elicit coordinated cellular response that result
in adaptation to the insult (Prives and Hall, 1999; Bates and Vous-
den, 1996). p53 functions as a transcription factor inducing
MDM2, Bax or IGF-BP3, and represses myc, fos or Bcl2. p53 also
induces genes that directly interfere with the cell cycle such as
p21waf1, 14-3-3s or GADD45. Either, 14-3-3s or GADD45 over-
expression arrests cells at G2/M by inhibiting cycB/CDC2
activity. In cells containing wild type p53, g-irradiation causes G1
arrests due to a p53-dependent activation of p21
cip1/waf1. Further-
more, other oncogenes or tumour suppressors function through
direct or indirect derregulation of p53 or pRb pathways such as
MDM2, p14/19
ARF, p33
ING1, BMI-1, BRCA1, or viral oncogenes
as HPV E6/E7, E1a, E1b or SV40 T antigen.
Given that the ultimate goal of cancer research is to ﬁnd the
complete cure for as many tumour types as possible, the identiﬁca-
tion of cell cycle targets may decisively inﬂuence the outcome of
therapy.
APPROACHES TO CDK INHIBITION
Because of the complex nature of its regulation, pharmacological
modulation of CDK function was thought to be improbable.
However, with the advent of newer biological probes and techni-
ques, modulating CDK activity can be approached via multiple
modes for therapeutic intervention.
Chemical inhibitors of CDK
CDKs are small ser/thr kinases that display 11 common sub-
domains shared by all protein kinases. The ATP-binding site,
located in a deep cleft between the two lobes of the protein,
contains the catalytic residues, which are conserved across eukaryo-
tic protein kinases (Pavletich, 1999). Small molecules that interact
speciﬁcally with the ATP-binding site of CDKs represent the most
immediate opportunity to allow pharmacological design. A group
of compounds that occupy the ATP-binding pocket of the enzyme
and are competitive with the ATP have been characterized (Meijer
et al, 1999; Mani et al, 2000; Fischer and Lane, 2000; Senderowicz
and Sausville, 2000). Chemical CDK inhibitors can be subdivided
into the following eight families: purine derivatives (including 6-
DMAP, olomucine, roscovitine and purvanolol), butyrolactone I,
ﬂavopiridols, staurosporine and derivatives, toyocamycin, 9-hydro-
xyellypticine, polysulphates (including suramin) and paullones,
although new ones are constantly being discovered. Compounds
such as staurosporine and their derivatives, suramin and 6-DMAP
are relatively non-speciﬁc kinase inhibitors. Compounds much
more selective for CDK inhibition versus other kinases include
ﬂavopiridol that inhibits all CDKs, however, buty-rolactone I,
olomucine and roscovitine, purvanolol and paullone derivatives
are relatively selective for CDK1(CDC2) and CDK2, but spare
CDK4 and CDK6. The antiproliferative effects of these compounds
on the growth of several human cell lines has been well documen-
ted (Sausville et al, 1999; Meijer et al, 1999). The effects in vivo of
these compounds paralleled the in vitro efﬁciency and were further
conﬁrmed with the use of dominant negatives, the overexpression
of natural CKIs and the microinjection of inactivating antibodies
or antisense technologies (van den Heuvel and Harlow, 1993).
Some of these CDK inhibitors have been piloted in the clinic
and the ﬁrst data from these clinical trials are available (Sendero-
wicz et al, 1998; Stadler et al, 2000; Schwartz et al, 2001).
Flavopiridol, the ﬁrst CDK modulator tested in clinical trials,
demonstrated interesting clinical features: cell cycle block at G1
and G2 (consistent with its inhibition of CDK2 and CDK1), induc-
tion of apoptosis, promotion of differentiation, inhibition of
angiogenic processes and modulation of transcriptional events.
Besides the direct effects ﬂavopiridol depletes cyclin D1 and D3
by transcriptional repression (Senderowicz, 2001). This may be a
consequence of the direct inhibition of CDK9-cyclinT (also known
as P-TEF, positive transcription elongation factor). Interestingly, in
contrast with other CDKs, ﬂavopiridol was not competitive with
ATP (Chao et al, 2000). P-TEF is a required cellular cofactor for
the human HIV transactivator Tat. Flavopiridol blocked Tat trans-
activation and blocked HIV-1 replication in vitro assays. This
biochemical effect indicates that ﬂavopiridol should be tested in
HIV malignancies including HIV-lymphomas. Initial clinical trials
Table 1 Mammalian cyclin-dependent kinase (SDK) complexes
Quinasa Regulatory subunit Substrate Function
CDC2 cyclin A & B pRb, NF, histone H1 G2/M
CDK2 cyclin A, E pRb, p27 G1/S, S
CDK3 cyclin E E2F1/DP1 G1/S
CDK4 cyclin D1, D2 & D3 pRb G1/S
CDK5 p35, cyclin D1 & D3 NF, Tau Neuronal differentiation
CDK6 cyclin D1, D2 & D3 pRb G1/S
CDK7 cyclin H CDC2, CDK2/4/6 CAK
CDK8 cyclin C RNA pol II Transcript. regulation
CDK9 cyclin T pRb, MBP G1/S
Table 2 Cell cycle regulatory elements involved in human neoplasia
Protein Alteration Tumour
CDK4 Mutation Melanoma
cyclin D1 Overexpression Breast and prostate cancer, parathyroid
adenoma, gastric and esophagic carcinoma,
multiple myeloma
cyclin D2 Overexpression Colorectal carcinoma
cyclin E Overexpression Breast, ovary and gastric carcinoma
cyclin A Overexpression Hepatocellular carcinoma
CDC25A Activation Head and neck cancer, NSCLC
CDC25B Activation Breast cancer, lymphomas, head and
neck cancer, NSCLC
p27
Kip1 Inactivation/ Colon, breast and prostate cancer
degradation
p57
Kip2 Deletion/inactivation Beekwith-Widemann syndrome
p16
INK4a Deletion/inactivation Melanoma, lymphomas, NSCLC,
mutation pancreatic carcinoma
p15
INK4b Deletion/inactivation Leukemia, lymphomas
pRb Inactivation Retinoblastoma, SCLC, sarcoma
and bladder carcinoma
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with a variety of tumour types, including non-Hodgkin’s lympho-
mas, renal, colon and prostate cancers. The second CDK
modulator tested in clinical trials is the staurosporine derivative
UCN-01. UCN-01 also blocks cell cycle progression and promotes
apoptosis. Moreover, UCN-01 may abrogate checkpoints induced
by genotoxic stress due to inhibition of Chk-1 kinase. UCN-01
showed a long plasma half-life (approximately 600 h) due to bind-
ing to the alpha-1-acid-glycoprotein. Clinical activity was detected
against melanoma, lung cancer and non-Hodgkin’s lymphoma.
Phase II trials with these compounds in other schedules or in
combination with standard chemotherapic agents are ongoing.
Protein- and peptide-based inhibitors
CKIs combined with adenovirus vectors as vehicles for delivery and
expression are a powerful approach to examine therapeutic applica-
tions of CDK inhibition. Introduction of p16
INK4a in tumour cells
with functional pRb induces growth arrest of the cells at G1 phase
(Jin et al, 1995; Craig et al, 1998). Similar results have been
obtained with pRb and other members of the INK4 family (Schrei-
ber et al, 1999). Adenovirus expressing either p21
cip1/waf1 or p27
kip1
in cancer cell lines also demonstrated both in vitro and in vivo
growth inhibition (Chen et al, 1996; Craig et al, 1997).
Based on this, the strategy of using small peptides that mimic
the effects of endogenous CDK inhibitors is being developed.
Several carriers have been tested that introduce peptides into
cells. When a 16-amino acid transmembrane carrier segment
derived from the Drosophila antenappedia protein was linked to
the third ankyrin repeat of the p16
INK4a protein and inserted into
cells, Rb-dependent G1 arrest was observed (Fahraeus et al, 1996).
In a breast-derived cell line, the chimera containing antennapedia
peptide and the carboxyl-terminal residue of p21
cip1/waf1, had high-
er speciﬁcity for cdk4/cyclin D than for cdk2/cyclin E and arrested
the cells in G1 phase (Ball et al, 1997). In contrast, in vitro, the
chimera containing amino-terminal peptides of p21
cip1/waf1, inhib-
ited both cdk1 and cdk2, and cells were arrested in all phases of the
cell cycle (Bonfanti et al, 1997).
Chen et al (1999) have shown that 8-amino acid peptides
derived from the putative cyclin-cdk2-binding region of p21
cip1/
waf1 and E2F1 linked to N-terminal residues derived from human
immunodeﬁciency virus Tat protein or antennapedia protein can
block cells in S phase. This effect was associated with a loss of
cdk2 activity. Although all of the cells tested with these chimeras
showed clear evidence of G1/S-phase arrest, immortalized/trans-
formed cells were more prone to apoptotic cell death.
In another approach, a 20-amino acid peptide, identiﬁed by use
of a combinatorial library, speciﬁcally binds cdk2 and inhibits its
activity at low nanomolar concentrations in vitro (Colas et al,
1996). This peptide could act by blocking the interaction of the
catalytic subunit with substrates or cyclin cofactors.
Altering regulatory pathways
The depletion of the cyclin partner leads to CDK activity inhibi-
tion. Depletion of cyclin D1 from tumour cell lines with
antisense fragments induced antiproliferative effects that were
synergistic with other drugs (Schrump et al, 1996; Kornmann et
al, 1998). Inhibition of either cyclin A or E synthesis or activity
through microinjection of plasmids encoding antisense cyclin
cDNA or afﬁnity-puriﬁed anti-cyclin antibodies during G1 phase
inhibited DNA synthesis, providing a basis for the use of this strat-
egy as a therapeutic approach.
Apart from the use of antisense technologies to deplete the
tumour cells from speciﬁc cyclins and/or CDKs, several
compounds can inhibit tumour progression by modulating the
levels of cell cycle proteins. In breast carcinoma cells, antiestrogens
and retinoids inhibit the expression of cyclin D and other cell cycle
related proteins inhibiting CDK activity. In some systems rapamy-
cin treatment was associated with a decline in cyclin D1 and
prevents IL-2-stimulated degradation of p27
kip1. Cyclotoxic effects
of ﬂavopiridol may be also potentiated by an induced decrease
in the stability of the mRNA of the antiapoptotic protein Bcl2.
Other molecules, such as lovastatin, block cells at G1 concomitant
with p21
cip1/waf1 and p27
kip1 induction and CDK inactivation. Buti-
rate, a differentiating agent, suppresses the proliferation of tumour
cells correlating with an increase in p21
cip1/waf1 and a decrease in
pRb phosphorylation.
Although it seems unclear that the growth inhibitory effects of
these compounds are solely due to these modulating effects, they
may contribute to the overall antiproliferative effects observed in
preclinical studies.
CDC25
CDC25 is a dual-speciﬁcity phosphatase, which removes inhibitory
phosphorylations on Thr14 and Tyr15 residues on the ATP anchor
motif of CDKs, activating the kinase. CDC25 has, therefore, been
involved in cell transformation and tumorigenesis, checkpoint
control and apoptosis (Draetta and Eckstein, 1997). Inhibition of
CDC25A activity in HeLa cells using antibodies which inhibited
cell division, resulted in the accumulation of cells with mitotic-like
phenotype and death (Galaktionov and Beach, 1991). Inhibition of
CDC25B using antisense approach lead to delay in S phase with
subsequent antiproliferative effects (Garner-Hamrick and Fisher,
1998). Based on this information, the CDC25 family has been
the subject of a screen for inhibitory compounds.
A number of metal anions are speciﬁc inhibitors of PTPases.
Vanadate and tungstate have similarities with the phosphate group
and can bind to the active site covalently. Glyoma cells treated with
some vanadate derivatives arrest at the G2/M transition coinciding
with a hyper phosphorylation of CDK1 and a dramatic decrease of
its kinase activity (Faure et al, 1995). Other inactivating
compounds found, such as dephostatin or nitric oxide itself can
deactivate PTPases, perhaps by oxidation of the catalytic cystein
residue. Such a redox mechanism has been suggested as a general
regulatory mechanism in vivo. There is a moderate amount of
CDC25 inhibitory compounds (such as sulﬁrcin, DNAcins, vitamin
K derivatives, dysidiolide, alkyllysophospholypids or naphtoqui-
none analogues) that have shown anti-tumour activity. However,
most of them are still in preclinical studies (Eckstein, 2000). A
few of them (such as hexadecylphosphocholine) have been studied
in clinical trials against skin tumours and lung carcinomas. The
results were unsatisfactory due to side effects, but the SAR of these
compounds continue.
Modulation of proteasome machinery
Sequential turnover of certain cell cycle regulators, including
cyclins and CKIs p21
cip1/waf1 and p27
kip1, are mediated by the
20S proteasome, which promotes proteolytic degradation through
the ubiquitin/proteasome pathway. Increased turnover of these
cyclins are associated with the loss of CDK activity. On the other
hand, the inhibition of p21
cip1/waf1 or p27
kip1 speciﬁc degradation
could induce CDK inhibition through accumulation of the CKI.
However, although theoretically possible, a further complication
lies in the net effect and/or speciﬁcity of modulating proteasomal
pathways. Non-speciﬁc modulation may alter many signalling
pathways making difﬁcult the prediction of the ﬁnal cellular effect.
OTHER RELATED APPROACHES
E2F and apoptosis
Apoptosis as a consequence of Rb inactivation is largely dependent
upon wild-type p53 function. This ﬁnding is consistent with the
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also inactivated. It is also a likely explanation why DNA tumour
viruses such as SV40, adenovirus, and human papilloma virus
(HPV) encode proteins that target both Rb and p53. Given that
ectopic expression of E2F1 can induce p53-dependent apoptosis
(Wu and Levine, 1994), it is likely that deregulation of E2F1 parti-
cipates in this protective apoptotic response as a consequence of Rb
inactivation. The loss of this Rb-E2F1 apoptotic pathway may well
explain why mice lacking E2F1 are predisposed to cancer. This is
also being used to promote tumour cell death. Adenovirus
mediated overexpression of E2F1 induced cell death in gastric
carcinoma both in vitro and in mouse models (Fueyo et al,
1998). The apoptotic effect was more potent in the presence of
other cell cycle inhibitors such as olomucine or roscovitine.
Adenovirus expression of E2F enhances the anticancer effect of
p53 in glyomas (Mitlianga et al, 2001). E2F1 also inhibits
MDM2 expression in MDM2-overexpressing tumours by inducing
apoptosis, presumably by restoring p53 activity (Yang et al, 1999).
Adenovirus mediated E2F1 gene transfer efﬁciently induced apop-
tosis in melanoma cells. Interestingly, this effect was observed
independently of p53 status (Dong et al, 1999). Similar effects were
observed in head and neck, breast and ovarian carcinoma cell lines.
G2/M Checkpoint
The Polo-like kinase 1 (Plk1) is a highly conserved mitotic serine/
threonine kinase which is commonly overexpressed in cancer cell
lines (Golsteyn et al, 1996; Yuan et al, 1997). Plk1 positively regu-
lates mitotic progression by activating the CDC25C-CDK1
ampliﬁcation loop and by regulating late mitotic events, primarily
the ubiquitin-dependent proteolysis. Antisense against Plk1 speciﬁ-
cally inhibits cell proliferation of cancer cells in cell culture and in
the nude-mouse tumour model, but did not inhibit growth and
viability of primary cells.
Defects in pathways essential for mitotic regulation are likely to
be implicated in the cascade of events leading to aneuploidy and
neoplasia. Exogenous overexpression of AIM-1 increases ploidy
and aneuploidy in human cells (Tatsuka et al, 1998). Overexpres-
sion in colorectal tumour cell lines is thought to have a causal
relationship with multinuclearity and increased ploidy. Errors in
cytokinesis caused by AIM-1 overexpression is a major factor in
the predisposition to cancer. On the other hand, Aur2 has also
been implicated in oncogenesis, probably inducing defects in kine-
tochore function leading to chromosome instability and human
tumours (Goepfert and Brinkley, 2000). Although further studies
are needed to provide a clearer deﬁnition of how these kinetic
proteins are linked and regulated in normal mitosis and cancer,
a defective mitotic apparatus and centrosome number are central
and causative in chromosome missegregation and cancer. These
proteins may provide new molecular targets to develop G2/M
acting compounds inhibiting unrestricted proliferation.
CONCLUDING REMARKS
Whilst still being at the beginning of a new era in drug discovery, it
is clear that the information that is accumulating concerning the
basic mechanisms that govern the cell cycle offers new hope and
promise for developing a novel class of future medicines that speci-
ﬁcally target aberrant proliferation. In this respect, there can be
little doubt of the value of targeting the cell cycle in drug discovery.
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